Artiva expands Board with appointment of Dan Baker, M.D

Artiva (ARTV) Biotherapeutics announced the appointment of Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker brings over two decades of drug development experience in the pharmaceutical industry. He is currently the interim Chief Development Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at Johnson & Johnson, Janssen/Centocor J & J (JNJ)… most recently as the Vice President of Immunology R&D. Prior to Cue Biopharma, (CUE) Dr. Baker served as CEO and Founder of Kira Biotech Pty Ltd, a biotechnology company advancing novel drugs targeting immune system disorders. During his tenure at J & J, he led the clinical development of major immunology and inflammatory drugs including Remicade, Simponi and Stelara, which achieved over $20B in peak sales as well as other major clinical drug programs. Dr. Baker also previously served as Executive Director on the board of directors of Galapagos Therapeutics. He holds a B.A. in Biology from Gettysburg College and an M.D. from the University of Pennsylvania. Dr. Baker completed his medical residency at Hershey Medical Center and fellowship in Rheumatology at the University of Pennsylvania, followed by a research fellowship in Rheumatology at Mass General Hospital. He continued on as part of the faculty of the University of Pennsylvania for 18 years before taking on industry roles.